Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report

Figures & data

Figure 1 Secukinumab therapy. Before initiation of secukinumab therapy.

Figure 2 After 24 weeks of secukinumab therapy.

Data Sharing Statement

The data that support the findings of this study are available on request from the corresponding author.